Luye Pharma Group Ltd. (FRA:LUP)

Market Cap	1.17B +5.4%
Revenue (ttm)	768.16M +4.1%
Net Income	75.34M +31.1%
EPS	0.02 +26.7%
Shares Out	n/a
PE Ratio	15.49
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	825
Open	0.2900
Previous Close	0.2900
Day's Range	0.2900 - 0.2900
52-Week Range	0.2140 - 0.4820
Beta	n/a
RSI	48.35
Earnings Date	Mar 30, 2026

About Luye Pharma Group

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surg...

• Industry: Pharmaceutical Preparations
• Founded: 1994
• Employees: 5,115
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LUP

Financial Performance

In 2025, Luye Pharma Group's revenue was 6.31 billion, an increase of 4.07% compared to the previous year's 6.06 billion. Earnings were 618.75 million, an increase of 31.12%.

Financial numbers in CNY